Summary This study evaluated the relationship between prechemotherapy cortisol and 5-hydroxyindoleacetic acid (5-HIAA) excretion and chemotherapy-induced emesis. The urinary excretion of cortisol and the serotonin metabolite 5-HIAA in the night before chemotherapy administration were measured in 28 and 49 female patients receiving > 300 mg m-2 carboplatin. Vomiting and nausea were documented over a 3 day observation period. Lower basal cortisol excretion was significantly correlated with vomiting with or without nausea occurring within the observation period. 5-HIAA showed only a weak correlation with emesis on days 1-3, but low 5-HIAA excretion was correlated with a higher proportion of patients vomiting on days 2 -3 following chemotherapy. Low basal cortisol excretion might be useful as a predictor for chemotherapy-induced emesis and therefore should be evaluated prospectively in future studies.
Vomiting and nausea are distressing side-effects of cytostatic drug treatment (Coates et al., 1983) and efficient anti-emetic prophylaxis is mandatory for the maintenance of life quality and the patients' compliance with chemotherapy. Cisplatin, carboplatin and cyclophosphamide are widely used cytostatics which possess a remarkable emetogenic potential. Treatment without anti-emetic prophylaxis leads to emesis in the majority of patients (Gralla et al., 1981; Martin et al., 1990; Beck et al., 1993) . The combination of 5-hydroxytryptamine-3-receptor (5-HT3) antagonists with corticosteroids represents the most effective anti-emetic treatment in platinum-based and cyclophosphamide-based chemotherapy (Roila et al., 1991; Italian Group for Antiemetic Research, 1995) . These clinical experiences as well as experimental data (Cubeddu et al., 1990; Schworer et al., 1991; Miner et al., 1987; Fredrickson et al., 1992) indicate a role for serotonin and corticosteroid metabolism in the pathophysiology of emesis. The mechanism of anti-emetic action of the 5-HT3 antagonists mainly reflects their capability of blocking 5-HT3 receptors which are believed to play a crucial role in the afferent part of the emetic reflex. The mechanisms of the antiemetic action of corticosteroids are still unclear: increased 5-HT turnover or reduced 5-HT synthesis (Young, 1981; Munck et al., 1984) or an affection of the permeability of the blood -brain barrier (Livera et al., 1985) are in discussion. However, neither 5-HT3 receptor antagonists nor corticosteroids provide complete control of chemotherapyinduced emesis in all patients and there is a remarkable interindividual variation of susceptibility to emetogenic stimuli. The individual predisposition for emesis is determined by not yet completely described risk factors.
Two groups of risk factors for chemotherapy-induced emesis have been identified: factors related to the chemotherapy regimen and those related to the individual patient. The first group contains the type of cytostatics used, the combination of different drugs and the chemotherapy dose. The second group contains gender, age, history of alcohol intake, susceptibility for motion sickness, chemotherapy experience and biochemically measurable parameters such as noradrenaline (Fredrickson et al., 1994) and cortisol (Fredrickson et al., 1992; Hursti et al., 1993) . However, methodological problems of the latter studies make it difficult to draw final conclusions regarding the relation between cortisol metabolism and emesis. The major methodological problems in the Scandinavian studies were: patients with single-day and multiple-day chemotherapy regimens were not analysed separately, the sample collection period was not standardised and the analysis of emesis was performed between patients with 0-2 vs >2 emetic episodes instead of patients with and without emesis.
The aim of this study was to evaluate the relation between pre-chemotherapeutic 5-HIAA and cortisol excretion levels and chemotherapy-induced emesis in carboplatin-treated female patients. This analysis should add information about the role of 5-HT and cortisol metabolism in the pathophysiology of chemotherapy-induced emesis.
Methods Patients
A total of 54 patients who received a carboplatin-based chemotherapy regimen gave informed consent and were enrolled into the study. Five Sample collection and analysis The prechemotherapeutic urine samples were collected in a standardised time period from 20.00 to 08.00 the night before chemotherapy. The urine was stored in dark containers and the volume was recorded. A 10 ml aliquot was taken at the end of the collection period and frozen at -20°C until measurement. All measurements were performed with commercially available immunological assays. Cortisol was measured with a solid-phase fluorescence immunoassay (Delfia Cortisol kit, Kabi Pharmacia). No pretreatment was needed for this measurement procedure. Urine (20 Ml) was directly inserted and each sample was analysed twice for the purpose of internal control. The intra-assay variation coefficients were < 10% and the interassay variation coefficients were < 12% as measured with Lyophocheck quality controls (Biorad). 5-Hydroxyindoleacetic acid (5-HIAA) was measured with a fluorescence polarisation immunoassay (5-HIAA FPIA kit, Abbott Diagnostics). The preparation procedures of the urine samples are reported elsewhere (du Bois et al., 1995) . Every measurement series was accompanied by an internal control. Intra-assay variation coefficients were <10% and interassay variation coefficients were <8%. The measured concentrations were multiplied by the urine volume to calculate the amounts of 5-HIAA and cortisol excreted over 12 h the night before chemotherapy. Analysis was based on the comparisons between patients with and without emesis and between patients with and without emesis and/or nausea. Emesis and emesis with or without nausea were analysed separately for day 1, days 2-3 and days 1-3.
The relationship between emesis and the quantitative variables of cortisol and serotonin metabolism was analysed in two ways. First we compared patients with or without emesis with respect to the distribution of the measured variables by using boxplots (retrospective analysis). Significance was tested by the Wilcoxon test. Second, we considered the probability of emesis as a function of the quantitative variables (prospective analysis). These functions are shown by a running mean smoother. Corresponding P-values were based on the Spearman correlation coefficient.
Results
Emesis was observed in 37% of all patients on days 1-3. On the day of chemotherapy (day 1) 16% showed vomiting while 31% suffered from at least one emetic episode on days 2-3. Vomiting and/or nausea occurred more frequently. In all 49% of patients suffered from vomiting with or without nausea on days 1-3. Altogether 41% and 33% of patients showed vomiting with or without nausea on day 1 and days 2-3 respectively. The subgroup of patients in whom cortisol was analysed showed emesis on day 1 in 14%, emesis on days 1-3 in 43% and emesis on days 2-3 in 43%. Emesis with or without nausea was observed in 36% on day 1, 50% on days 1-3 and 50% on days 2-3 respectively. All patients who vomited on days 2-3 had also vomited on day 1. Therefore, analysis of emesis on days 1-3 and emesis on days 2-3 showed similar results in the subgroup of patients in whom cortisol excretion was analysed. However, the results are presented separately to make them comparable with the results of the 5-HIAA group. In the latter group some patients started vomiting later than day 1 and results regarding emesis on days 1-3 differ from results based on the analysis of emesis on days 2-3.
5-Hydroxyindoleacetic acid (5-HIAA)
The retrospective comparison of pretherapeutic 5-HIAA excretion did not reveal any significant differences between patients with and without emesis and/or nausea over days 1-3 (Figure 1c ). Median 5-HIAA excretion was 267 Mg with 25-75% quartiles being 187-313 ,ug in patients with emesis, and 230 Mg (155-325 Mg) in patients without emesis and/or nausea (P=0.54). Again, analysis with respect to emesis and/ or nausea on day 1 showed no significant difference (P = 0.48; Figure la) . In contrast, the comparison between patients with and without emesis and/or vomiting on days 2-3 reveals a significant difference with lower 5-HIAA excretion levels in patients suffering from nausea and/or vomiting (Figure lb) . 5-HIAA excretion levels were 200 Mg (126-238 Mg) and 275 Mg Mg) in patients with and without emesis and/or nausea on days 2-3 (P = 0.02). The comparison between patients with and without vomiting showed similar results and confirmed a relationship between vomiting on days 2-3 and pretherapeutic 5-HIAA excretion levels. Owing to the smaller numbers of events (i.e. emetic episodes) significance was not reached (P=0.057). Figure 2 shows the relationship between prechemotherapeutic 5-HIAA excretion levels and vomiting with or without nausea on days 1-3. Considering the whole observation period no correlation between 5-HIAA values and emesis was detected. The relationship was stronger when only vomiting was analysed but failed to reach significance (P =0.11 Emesis +/-nausea Figure 1 Prechemotherapy 5-HIAA excretion in patients with or without carboplatin-induced emesis +/-nausea on day 1 (a), days 2-3 (b) and days 1-3 (c) (median and 25-75% quartiles). Figure 3b ). The analysis regarding patients with or without vomiting and/or nausea on day 1 showed only a slight trend in favour of a higher cortisol excretion in patients who did not vomit (P= 0.28; Figure 3a ). The comparison regarding vomiting only for each observation period gave similar results (data not shown). Figure 4 shows the relation between pretherapy cortisol levels and emesis with or without nausea on days 1- correlation with cortisol values (P= 0.27). The latter analysis was hampered by the small numbers of events on day 1. Only four patients of the cortisol group vomited on day 1. Again, the analysis of days 2-3 coincided with that of days 1-3. The correlation between low cortisol levels and a higher risk for emesis was confirmed by the observation that vomiting within days 1-3 occurred only in patients with a cortisol excretion level below 110 jMg 12 h-1. In summary, low cortisol excretion level showed a close relation to emesis occurring within the 3 days following carboplatin-based chemotherapy.
Discussion
The involvement of 5-HT in the pathophysiology of chemotherapy-induced emesis has been documented in several studies. Particularly for cisplatin therapy, experimental as well as clinical data have contributed to the actual model of the pathophysiology of emesis. In short, cisplatin leads to an exocytotic release of 5-HT from the enterochromaffine cells in the upper gut which then binds to vagal 5-HT3 receptors causing depolarisation. The activation of afferent vagal neurones leads to a stimulation of brainstem neurones, the so-called 'vomiting centre'. The activation of the 'vomiting centre' starts a cascade of efferent activity which finally evokes emesis (for a review see Andrews, 1994) . Correspondingly, an increased excretion of 5-HIAA, the main metabolite of 5-HT, following cisplatin therapy has been observed (Cubeddu et al., 1992 Figure 3 Prechemotherapy cortisol excretion in patients with or without carboplatin-induced emesis on day 1 (a), days 2-3 (b) and days 1-3 (c) (median and 25-75% quartiles). , 1995) found elevated 5-HIAA excretion levels following platinum-based chemotherapy, but could not demonstrate any difference in post-chemotherapy 5-HIAA excretion depending on whether a patient vomits or not. The present study has evaluated prechemotherapeutic 5-HIAA excretion levels and emesis. 5-HIAA excretion showed only marginal differences between patients who vomited and those who did not when the whole observation period is considered for analysis. However, low 5-HIAA excretion might be related to emesis occurring on days 2-3 following carboplatin. These data make it worthwhile to evaluate further the role of serotonin in the pathophysiology of noncisplatin-induced emesis occurring later than on day 1. Corticoid metabolism is probably also involved in the pathophysiology of chemotherapy-induced emesis. Corticosteroids have shown a remarkable anti-emetic efficacy and a relationship between anti-emetic efficacy of corticosteroids and lower basal cortisol excretion has been reported (Hursti et al., 1993) . The present data in carboplatin-treated female patients confirm these findings and indicate a close relationship between cortisol excretion levels and the risk of emesis. Again, the correlation between lower cortisol excretion and emesis is weaker when analysis is limited to day 1.
Cortisol excretion levels were superior to 5-HIAA values in predicting carboplatin-induced emesis and might be useful in the description of the individual risk for chemotherapyinduced emesis. The analysis of the relationship between cortisol and emesis was based on a retrospectively defined cut-off. Therefore, results might be too optimistic. However, the present analysis helps to identify risk factors which should be considered for further studies. Our data are preliminary because only a selected group of patients (i.e. females) was enrolled. Nevertheless, this study can help design future protocols evaluating cortisol excretion prospectively. These future studies should help to define the role of cortisol excretion levels as risk factors and predictors of chemotherapy-induced emesis.
